Active Studies

The objective of this study is to compare the efficacy of Cognitive Behavioral Training for Insomnia (CBT-I) on improving cognitive function in older adults with symptoms of insomnia, determine the association between change in sleep measures and change in cognitive function, and to examine the efficacy of CBT-I on reducing the rate of Aβ deposition. Participants, ages 60-85, will be randomly assigned to a six-week CBT-I training or to an active control group. A sub-group of fifty CBT-I participants will undergo Florbetapir-Positron-emission tomography (PET) imaging during the one-year reassessment to examine the efficacy of CBT-I on reducing the rate of Aβ accumulation from baseline to one year post CBT-I.

The purpose of this study is to obtain information pertaining to the occurrence of antibodies
to investigational SPK-3006 and GAA, GAA activity and GAA antigen levels in the usual care
setting of Late-Onset Pompe Disease (LOPD) participants on an enzyme replacement regimen.
Additionally, a careful evaluation of laboratory and functional testing in patients with LOPD
may provide information to better understand the disease features and better drive the design
of a future interventional investigational gene therapy trial. An understanding of the
underlying status of liver and muscle health in individuals with LOPD may also inform best
surveillance during the conduct of gene therapy trials.

This is an open label, multi-center trial of tisotumab vedotin in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer.

The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.

This study will be an open-label trial to determine the functional effects of bilateral IA
injections of Zilretta into knee joints of 70 subjects with bilateral KL grade 2-4
symptomatic knee osteoarthritis (OA). Measurement and evaluation of outcomes at baseline, 6,
12 and 24 weeks will allow assessment of short and long-term effects, consistent with
Osteoarthritis Research Society International (OARSI) and Outcome Measures in Rheumatology
(OMERACT) recommendations.

<p>Brain activity likely to be involved in control of brain-computer interfaces (BCI) will be recorded by electroencephalography (EEG), a non-invasive technique. These recordings will be used to control a computer-based augmentative and alternative communication (AAC) device.

Pages